Comparative Pharmacology
Head-to-head clinical analysis: PURINETHOL versus ZYTIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PURINETHOL versus ZYTIGA.
PURINETHOL vs ZYTIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mercaptopurine is a purine antimetabolite that inhibits purine nucleotide synthesis and metabolism. It is converted intracellularly to 6-thioguanine nucleotides (6-TGNs), which incorporate into DNA and RNA, inhibiting their synthesis and function. It also inhibits de novo purine synthesis via feedback inhibition.
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor that selectively inhibits the enzyme CYP17 (17α-hydroxylase/C17,20-lyase). This inhibition blocks androgen production in the testes, adrenal glands, and prostate tumor tissue.
1.5-2.5 mg/kg orally once daily. Initial dose typically 50-75 mg/m²/day.
1000 mg orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal, in combination with prednisone 5 mg orally twice daily.
None Documented
None Documented
The terminal elimination half-life of mercaptopurine is approximately 1.5 hours. However, the active metabolite 6-thioguanine nucleotides have a half-life of 5-7 days, correlating with pharmacological effects.
The terminal elimination half-life of abiraterone is approximately 12 hours (range 9–18 hours) following oral administration, supporting twice-daily dosing.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 50% of elimination. Biliary excretion contributes to a minor extent (<10%).
Abiraterone is primarily eliminated via hepatic metabolism with less than 1% excreted unchanged in urine. Approximately 88% of a radiolabeled dose is recovered in feces (mainly as metabolites) and about 5% in urine.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent